The enduring mystery of lithium’s effectiveness against bipolar disorder

While modern society primarily associates lithium with batteries for smartphones and electric vehicles, its medical legacy is rooted in psychiatry. Introduced as a treatment for bipolar disorder in 1949, this straightforward medication has withstood decades of pharmaceutical innovation to remain the benchmark for managing one of the most complex mental health conditions.

According to Becci Strawbridge, a senior lecturer in psychological medicine at King’s College London, lithium’s chemical simplicity may be precisely what allows it to navigate the intricacies of bipolar disorder, a lifelong condition affecting approximately 36 million people globally.

Bipolar disorder is clinically characterized by profound shifts in mood and energy. Depending on the specific subtype, patients endure manic, hypomanic, or depressive episodes. Dr. David Cousins, a clinical senior lecturer at Newcastle University, notes that experiencing mania alone is sufficient for a diagnosis. He describes this state as the inverse of depression, marked by elevated mood, excessive drive, and risky hedonistic behavior, which he calls a highly disruptive and damaging condition.

Treating a disorder defined by such emotional extremes requires delicate balance. Interventions aimed at one pole can destabilize the other; for instance, administering antidepressants without an antimanic agent can trigger mania or worsen the illness’s trajectory.

Strawbridge highlights that few medications effectively address both ends of the bipolar spectrum. While doctors often prescribe combinations of antidepressants, antipsychotics, and mood-stabilizing anticonvulsants, lithium stands out for its ability to treat both depression and mania while primarily preventing relapse.

Lithium is typically administered as lithium carbonate tablets or lithium citrate liquid. Inside the body, these compounds dissociate into lithium ions. This simple ionic structure allows lithium to mimic sodium, enabling it to cross cell membranes and enter brain cells directly, whereas many other drugs act only on cell surfaces. This access allows the ion to distribute throughout the brain and interact with various cellular processes.

Although the exact mechanism remains elusive, researchers have identified several pathways. Victoria Wing, a clinical lecturer at the National Institute for Health and Care Research, explains that bipolar disorder involves disruptions in the monoamine system and neurotransmitters like dopamine and serotonin, which regulate reward, emotion, and cognition.

Furthermore, the small lithium ion inhibits an enzyme known as glycogen synthase kinase 3. This inhibition triggers broad downstream effects, including the regulation of gene activity, circadian rhythms, inflammation, and cell survival. Wing also notes that lithium promotes autophagy—the clearance of cellular debris and toxins—while providing antioxidant benefits and enhancing mitochondrial function.

Despite these benefits, lithium is not a universal cure. Approximately one-third of patients experience significant improvement, another third see moderate effects, and the final third show little to no response. Because identifying responders can take years due to the cyclic nature of the disease, early detection is crucial.

Additionally, lithium has a narrow therapeutic window, meaning the margin between an effective dose and a toxic one is small. Potential side effects include kidney and thyroid issues, frequent urination, and tremors. However, specialists emphasize that when managed correctly, the drug can be transformative. Wing reports that many patients describe lithium as lifesaving, though researchers continue to seek ways to fine-tune its application so more individuals can benefit.